IRVINE, Calif.--(BUSINESS WIRE)--Reverse Medical Corporation today announced the initial clinical use of their UNO™ Neurovascular Embolization System for intracranial use. The device has been granted European Union CE Mark approval to obstruct blood flow in the Neurovasculature.
Professor Marco Leonardi at Università di Bologna, Italy performed the initial UNO System clinical case. Professor Leonardi commented, “The UNO represents a unique device, specifically designed for rapid vessel sacrifice, reducing the time otherwise necessary for multiple coil deployments. I can see the UNO becoming a useful tool in my practice. Microcatheter deliverability is excellent within tortuous anatomy, and re-sheathability offers me confidence of placement accuracy”.
Reverse Medical President and CEO Jeffrey Valko, commented, “Tolerable neurovascular vessel sacrifice is often considered as a safe, cost effective alternative to aggressive and often risky vessel salvage. Intracranial vessel sacrifice has routinely involved multiple costly embolization coils and a lengthy procedure, with extensive fluoroscopy radiation exposure to both the patient and the clinical team. The UNO System has demonstrated immediate vessel occlusion upon target deployment from a rapidly delivered single implant, One and Done™! The unique device design features of Microcatheter deliverability, 100% resheathability, and superselective positioning have offered the Neurointerventionalist a new instrument, reaffirming our commitment to Neuro Endovascular innovation. It is always exciting and impressive, to observe technical innovation lead to clinical-use innovation”.
The Company will continue to confirm superior clinical device performance from the UNO System and begin commercialization in Europe this year through a network of expert regional distributors.
Reverse Medical Corporation is a privately held medical device company focused on expanding a technology driven pipeline of innovative, state-of-the-art endovascular treatments for a broad spectrum of peripheral and neurovascular disorders and disease. The company is based in Irvine, California.